Moonlake Immunotherapeutics Ordinary Shares had a rough day and is now down -5.08%. Investors weren't too impressed with the future outlook for the asset which caused some selling on weak demand.
It looks like Moonlake Immunotherapeutics Ordinary Shares isn't currently at a very decisive point in regards to support/resistance levels. Moonlake Immunotherapeutics Ordinary Shares hasn't shown a lot of strength recently, shareholders don't seem that energized about the asset's future prospects. MLTX might find some support at the 18.8 level, buyers might push the price back up from here. But it's not very clear what will happen.